UNSPSC 51334418: Timirdine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3I3H31VAS6. European Medicines Agency schedules Timirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11066MIG. Timirdine generally arises in the molecular formula C9H10CLN3S. The term TIMIRDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) Most nations schedule timirdine under HS 29341000 and SITC 51579.

As of Q4 2014, TIMIRDINE remains the US FDA Preferred Term for this commodity. Timirdine bears US NLM identifiers UMLS ID C2699946 and NCI Concept Code C76452. SMILES: CLC1CC(N)C(N2CCSC2=N)CC1.

UNSPSC 51334418 Timirdine (Commodity) covers pharmaceutical products and related medical supplies procured by state and local health agencies, counties, and cooperative purchasing alliances to support public health initiatives, emergency response programs, and community health services. Recent solicitations show state and local buyers acquiring naloxone kits for overdose response, safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products through both direct procurement and multi-state cooperative agreements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating states including Minnesota and Oregon). Vendors must typically meet pharmaceutical compliance requirements including FDA certification, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) adherence, and contractual relationships with established pharmaceutical wholesalers; most procurements require E-Verify compliance, drug-free workplace certification, and specified insurance coverages including commercial general liability and professional liability.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most visible procurement volume in cooperative purchasing frameworks that serve multiple jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with pricing weighted 75 percent on competitiveness, mandatory wholesaler relationships through AmerisourceBergen, Cardinal Health, or Morris & Dickson, and a 3 percent administrative fee on all contract purchases. Awards under MMCAP are effective July 1, 2026, with contract terms of two years for new vendors. No explicit set-aside designations appear in the recent opportunities reviewed.